about
mTOR inhibitors in advanced renal cell carcinomaTherapeutic challenges in renal cell carcinomaMetastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalitiesAutophagy suppresses RIP kinase-dependent necrosis enabling survival to mTOR inhibitionEverolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapyEverolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenibPhase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas.Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma.Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.Insulin and glucagon regulate pancreatic α-cell proliferationIntrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma.A polymorphism (rs2295080) in mTOR promoter region and its association with gastric cancer in a Chinese populationAnti-CD70 immunocytokines for exploitation of interferon-γ-induced RIP1-dependent necrosis in renal cell carcinoma.Meta-analysis identifies NF-κB as a therapeutic target in renal cancer.Immune profiling and cancer post transplantationDevelopment and validation of the functional assessment of cancer therapy-antiangiogenesis subscale.Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma.Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell cultureClinical experience with temsirolimus in the treatment of advanced renal cell carcinomaEmerging molecular classification in renal cell carcinoma: implications for drug development.Promising pharmacological profile of a Kunitz-type inhibitor in murine renal cell carcinoma modelPiperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma.Inhibition of mTORC1 kinase activates Smads 1 and 5 but not Smad8 in human prostate cancer cells, mediating cytostatic response to rapamycin.Combined mutation of Vhl and Trp53 causes renal cysts and tumours in miceTargeted therapy for renal cell carcinoma: The next lap.Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology.Post-transplant malignancy: reducing the risk in kidney transplant recipients.Clinical activity of mammalian target of rapamycin inhibitors in solid tumors.Kidney cancer pathology in the new context of targeted therapy.Modulating autophagy: a strategy for cancer therapyThe metabolic and toxicological considerations for mTOR inhibitors in the treatment of hepatocarcinoma.Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action.Neoadjuvant and adjuvant treatment of renal cell carcinoma.Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma.The promise of mTOR inhibitors in the treatment of colorectal cancer.Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomas.Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors.Risk evaluation and mitigation strategies: a focus on the mammalian target of rapamycin inhibitors.Interferon-γ-induced necrosis: an antitumor biotherapeutic perspective.Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms.
P2860
Q24612127-73422888-25B3-4215-97E9-1EF2D131FD6DQ26796702-5F9A5F71-8916-46DE-A070-4A063D78F6A1Q26852437-E0CB78C3-4666-4029-A77C-7D5C5B756C00Q27330047-7997E8C2-DB6F-42FB-A1E9-C2A1A5A016B9Q28079861-7F00D3F6-CE24-4E3C-861B-05320C9B78A4Q28765488-54B1F1AA-B706-4C4A-BF62-E9C5519BB20BQ30422022-A19CE100-E602-4C25-AA44-019E6914FB12Q33408127-8307EC9D-5382-486B-99A9-BCF9BBA784FDQ33423777-BA6ED83E-2D34-4745-A11B-C26CB5058BF8Q33808713-7F0EBB26-64C3-425A-BE34-F180D5660B75Q33960788-1E8FCBDF-A282-4250-9F15-57023D68BA60Q34653205-7AB8977F-B580-4A4D-A7B4-0A6F3D04C487Q34684399-92939AE5-02CB-4FE7-8D2E-5BCAC43B0961Q35014835-3F84BB43-D41C-4AAF-A66D-728529F958E0Q35050810-11F468C3-3ED9-4BFB-B85B-709AE5823EA2Q35602130-C14FC1BA-90ED-48A9-941C-8169FA9CA0D0Q35660948-45B869C1-0D75-4964-A960-F44E96260A25Q35679387-196468DD-23B0-4B84-9073-B9ABE602FF5FQ35797388-0443352F-36F6-42DA-A674-5BADF7760434Q36084718-23B06E3F-14E7-416F-BC97-D659C1B8FE11Q36114934-40C2446C-8ECB-4169-BA7B-860C8F111617Q36214648-53F32C24-58E3-49B2-A871-A41CAF9259CBQ36569202-1A379BD9-DC27-496B-BB57-84EDDEA74554Q37188593-E3711AE6-0170-42EB-9A15-0AE6805CB614Q37702529-43C9D688-E420-41CF-A904-16AC49110027Q37793095-446A8E0C-97F3-4B44-AF62-35AAF7D54335Q37863680-E6CF5052-2A65-4B24-AA4C-ECFE10DA1919Q37871915-4AC1A954-4AD3-4AB9-8D1C-B7301138D1C4Q37890209-11B49E7D-CB26-41F1-852C-7E8B04BB0AB6Q37940741-75C823DD-C407-4EE2-8715-EBDD8AA585FCQ37950012-54710D35-BB45-4CEF-9AC8-7902351D2BE3Q38016794-02EFAD96-97F9-43CC-B9FF-E2812530C86EQ38020243-4A405E94-5E53-4C74-9819-ADF1F9A49025Q38028411-08CDE838-4DFA-4CFE-B72F-31937CC2B8F5Q38043507-39DA5BE6-F677-4BA6-9CA2-A389587B824EQ38055499-A81EDC60-3C7F-4008-83D1-B66F0B85E9FDQ38074121-510736DA-EC24-4B41-A77A-73BCB0A0C9BCQ38085437-09E93B66-AF68-4BEB-B597-9E10E9379E84Q38097514-D17CA2F1-965C-4A3C-965B-F5350FAB60B0Q38187149-1BC75BD9-8039-493A-99DE-3F58BBD6A9D6
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting mTOR in renal cell carcinoma.
@en
Targeting mTOR in renal cell carcinoma.
@nl
type
label
Targeting mTOR in renal cell carcinoma.
@en
Targeting mTOR in renal cell carcinoma.
@nl
prefLabel
Targeting mTOR in renal cell carcinoma.
@en
Targeting mTOR in renal cell carcinoma.
@nl
P356
P1433
P1476
Targeting mTOR in renal cell carcinoma.
@en
P2093
Gary R Hudes
P304
P356
10.1002/CNCR.24239
P407
P433
P577
2009-05-01T00:00:00Z